T Cell DNA Damage Impedes Immunotherapy Durability

DNA damage in T cells significantly impairs the efficacy of immunotherapies, according to a review published in Cancer Biology & Medicine.

Researchers from Tongji Hospital and other institutions found that genotoxic stress within the tumor microenvironment (TME) creates a spectrum of lesions that limit the durability of immune responses.

Genotoxic Pressures Within the Tumor Microenvironment

The effectiveness of immune checkpoint blockers and CAR T cell therapy hinges on the functional integrity of T cells. However, these cells face intense genotoxic pressure in the TME. Rapid proliferation and T cell receptor (TCR) activation trigger replication stress and the accumulation of reactive oxygen species (ROS). Regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) actively starve lymphocytes of nutrients or introduce chemical modifications that impede cellular function.

Most clinical research has treated T cells as passive observers of tumor-intrinsic DNA damage. This review shifts that perspective, highlighting that T cells themselves sustain significant damage that limits the long-term success of cancer treatments. The authors emphasize that DNA damage is not a monolithic event but a nuanced spectrum requiring specialized repair mechanisms.

DNA Damage Repair Pathways Vary Across T Cell Subsets

The cellular response to DNA damage depends heavily on the type of lesion and the activation state of the T cell. Oxidative base lesions and single-strand breaks, common in the ROS-rich TME, rely on poly(ADP-ribose) polymerase (PARP) for repair. Conversely, double-strand breaks engage ataxia-telangiectasia mutated (ATM) and DNA-dependent protein kinase (DNA-PK) pathways.

Susceptibility to this damage is not uniform across all T cell subsets. Exhausted T cells (TEX) display the highest levels of phosphorylated ATM (pATM), signaling intense repair activity. Meanwhile, terminally differentiated effector memory T cells (TEMRA) show greater vulnerability than stem cell-like memory T cells (TSCM). The latter maintain higher DNA repair capacity and lower levels of pro-apoptotic markers like caspase-3.

Metabolic Drivers of Cellular Exhaustion

Chronic activation upregulates CD38, an NAD+ hydrolase that depletes the cellular NAD+ pool. Because PARP activity is NAD+-dependent, this depletion effectively cripples the T cell’s ability to repair its own DNA. Tumors further exacerbate this by competing for glucose and releasing nitric oxide (NO). The downstream effects are severe: impaired memory formation, reduced granzyme B and interferon-gamma production, and the upregulation of inhibitory receptors like PD-1 and TIM-3.

The research identifies a notable clinical paradox: PARP inhibitors, while intended to make tumors more immunogenic, can inadvertently trap PARP1 in T cells. This trapping mechanism may worsen T cell DNA damage, potentially undermining the very immunotherapy regimens they are meant to support.

Strategic Combinations to Protect Immune Function

The authors argue that the goal of future research should be smarter scheduling rather than simply increasing tumor-killing intensity. Protecting T cells without sacrificing antitumor efficacy requires a nuanced approach to combination therapies. Boosting NAD+ levels via β-nicotinamide monucleotide (NMN) or blocking CD38 has shown promise in mouse models by restoring PARP-dependent repair and improving T cell expansion.

The review identifies several ways to protect T cells without sacrificing antitumor activity:

  • Inhibiting inducible nitric oxide synthase (iNOS) to mitigate TME-driven damage.
  • Utilizing ATM or p38 inhibitors in combination with adoptive cell transfer.
  • Implementing sequential dosing or intermittent scheduling of DNA damage response inhibitors (DDRi).
  • Employing non-trapping PARP inhibitors or genetic editing of PARP1 within manufacturing pipelines.

Biomarkers for Clinical Stratification

To improve patient outcomes, the authors advocate for the adoption of specific biomarkers to monitor T cell health. They suggest that pATM and 8-hydroxy-2′-deoxyguanosine (8-OHdG) could serve as effective indicators for patient stratification. By measuring repair capacity and damage-associated phenotypes, clinicians could move away from treating immune toxicity as an afterthought and instead design trials that prioritize the durability of the immune response.

The framework proposed by the researchers suggests that integrating these monitoring techniques into standard trial design is the next logical step for advancing immunotherapy. The authors stress that T cells are not uniform, and future therapeutic strategies must account for these distinct subsets to ensure treatment longevity.

Photo of author

Sophie Lin - Technology Editor

Sophie is a tech innovator and acclaimed tech writer recognized by the Online News Association. She translates the fast-paced world of technology, AI, and digital trends into compelling stories for readers of all backgrounds.

Analysts Debate if Eisenkot’s Bloc is Less Right-Wing Than Netanyahu